GLP-1
The latest news about GLP-1: headlines, AI summaries and the full story from every source.
- China Approves Eli Lilly's Oral GLP-1 Weight-Loss Drug Orforglipron
- Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Development
- Eli Lilly Raises Revenue Forecast Amid Strong Zepbound Sales and Competition from Viking Therapeutics
- Eli Lilly's Oral GLP-1 Foundayo Shows Significant Improvement in Sleep Apnea Phase 3 Trial
- Eli Lilly's Foundayo Obesity Pill Shows Significant Reduction in Sleep Apnea Severity
- Novo Nordisk Reports Strong Third Quarter Results Driven by Oral Wegovy Growth
- Novo Nordisk Reports Q3 2026 Growth Driven by GLP-1 Portfolio and Wegovy Expansion
- UBS Initiates Coverage on Viking Therapeutics with Buy Rating and $94 Price Target
- Eli Lilly Raises Price Target Amid Strong Third Quarter Earnings and Obesity Drug Growth
- Novo Nordisk Files Lawsuit Against Eli Lilly Over GLP-1 Advertising Claims
- Samsung Biologics Acquires PolyPeptide Group in $1.8 Billion Deal
- GLP-1 Weight-Loss Drugs Being Tested on Overweight Cats
- Johnson & Johnson CEO Announces Company Will Not Enter Obesity Drug Market
- PatentVest Report Highlights Muscle-Preservation Category as Emerging Opportunity for Obesity Therapeutics
- PatentVest Report Analyzes Triple-Agonist Obesity Drug Development and Patent Strategies
- First Ozempic Generics Approved in Canada, Seen as Test Case for Novo Nordisk
- Barclays Raises Price Target for Eli Lilly to $1,400 Amid Tirzepatide Momentum
- Amble Health Launches Amble Cares Program to Provide Affordable Weight Loss Treatments to Low-Income Americans
- Amneal Reports Q2 2025 Earnings with Revenue Growth
- Bank of America Maintains Bullish Stance on Eli Lilly Despite Lowered Price Target
- West Pharmaceutical Services Reclaims Momentum with Strong Q1 2026 Results
- Zealand Pharma's GLP-1 Candidate Achieves 17% Weight Loss in Late-Stage Trial
- Eli Lilly's Weight Loss Pill Prescriptions Reach 1,390 in First Week of Sales